The market for plasma fractionation achieved a worth of US$ 32 Billion by 2022. Additionally, during the evaluation period of 2022-2032, there is an anticipated surge in growth at an impressive CAGR of 7.3%, resulting in a valuation of US$ 65 Billion.
In the global healthcare industry, the plasma fractionation market holds a pivotal role by providing crucial therapeutic products derived from blood plasma. These products, obtained through the process of plasma fractionation, include albumin, immunoglobulins, clotting factors, and more, all of which are instrumental in treating various medical conditions.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4806
Market Opportunity:
The plasma fractionation market is poised for remarkable growth, offering a multitude of opportunities for both established and emerging players. Several factors contribute to the promising outlook for this market:
Rising Healthcare Needs: The prevalence of autoimmune diseases, hemophilia, and immunodeficiencies is on the rise, creating a substantial patient pool in need of plasma-derived therapies. This growing patient base presents an ever-expanding market for plasma fractionation.
Advancements in Fractionation Technology: Ongoing innovations in plasma fractionation technology have enabled the development of more efficient and safer production processes. These advancements are expected to enhance the quality and yield of plasma-derived products, thus increasing their accessibility and affordability.
Expanding Geriatric Population: As the global population ages, the demand for plasma-derived products is expected to surge. Elderly individuals are more susceptible to various medical conditions that require these therapies, resulting in a substantial market opportunity.
Increasing Healthcare Expenditure: The growing healthcare expenditure in both developed and emerging economies is likely to drive investments in the plasma fractionation industry. This, in turn, will support research and development, leading to the introduction of new and improved therapies.
Market Challenges:
While the plasma fractionation market presents significant opportunities, it is not without its challenges:
Regulatory Compliance: Stringent regulatory requirements for the collection, processing, and distribution of blood plasma pose a significant challenge for market players. Compliance with these regulations is crucial for ensuring product safety and quality.
Ethical and Safety Concerns: The collection of plasma from donors has raised ethical concerns in some regions, particularly when compensation is involved. Additionally, ensuring donor and product safety is paramount to maintaining the trust of the public.
Supply Chain Vulnerabilities: The plasma fractionation supply chain is susceptible to disruptions, such as those caused by natural disasters or pandemics. These disruptions can impact the availability of plasma-derived products.
Competition: The plasma fractionation market is becoming increasingly competitive with the entry of new players. This intensifying competition may exert downward pressure on product pricing and margins.
Key Players:
- Grifols S.A.
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Kedrion S.p.A
- LFB S.A.
- Biotest AG
- Sanquin
- Bio Products Laboratory Ltd.
- Intas Pharmaceuticals Ltd
Competitive Landscape:
Key players in this market are implementing various strategies to enhance their market position, including mergers and acquisitions, regional expansion, and strategic collaborations. Notable market developments include Terumo Blood and Cell Technologies' establishment of a state-of-the-art production plant in Douglas County, Colorado in May 2022. The facility, which cost USD $250 million, aligns with the company's mission of improving healthcare and serving more people by producing single-use collection sets for the recently FDA-approved Rika Plasma Donation System. Additionally, CSL Behring expanded its manufacturing facility in Broadmeadows, Victoria in May 2022 to increase processing capacity for Australia's growing annual domestic plasma collections, in accordance with the National Fractionation Agreement between the National Blood Authority and CSL Behring.
Key Segments Covered in the Plasma Fractionation Industry Survey
- By Product :
- Albumin
- Immunoglobulins
- Intravenous Immunoglobulins
- Subcutaneous Immunoglobulins
- Others
- Coagulation Factors
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Prothrombin Complex Concentrates
- Fibrinogen Concentrates
- Others
- Protease Inhibitors
- Others
- By Method :
- Centrifugation
- Depth Filtration
- Chromatography
- Others
- By Application :
- Neurology
- Hematology
- Oncology
- Immunology
- Pulmonology
- Others
- By End User :
- Hospitals & Clinics
- Clinical Research
- Others
- By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=4806
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: [email protected]
